Each 5 ml syrup contains Ketotifen Fumarate BP 1.38 mg equivalent to Ketotifen 1 mg.
Tink is a preparation of Ketotifen, which has anti-allergic properties and has been used similarly, to sodium cromoglycate in the prophylactic treatment of asthma. It also has the properties of an antihistamine. Tink (Ketotifen) possesses marked anti-anaphylactic properties and is effective in preventing asthmatic attack. Tink (Ketotifen) exerts as sustained inhibitory effect on histamine reactions, which can be clearly dissociated from its anti-anaphylactic properties. Experimental investigations in asthmatic subjects have shown that Ketotifen is as effective orally as a selective mast cell stabilizer administered by inhalation. Where other antihistamines were ineffective in those tests. The effectiveness of Ketotifen has been studied in long term clinical trials. Asthma attacks were reduced in number, severity and duration and in some cases, the patients were completely freed from attacks. Progressive reduction of corticosteroids and/or bronchodilators was also possible in the use of Tink (Ketotifen). The prophylactic activity of Tink (Ketotifen) may take several weeks to become fully established.
Tink (Ketotifen) is indicated in the following conditions-
- For the prophylactic treatment of bronchial asthma
- Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis
- For alleviating the complications of itching, pain and tenderness associated with neurofibroma
- Symptomatic treatment of allergy such as hayfever, urticaria
Dosage and Administration
Children above 3 years: 1 mg or 5 ml (1 teaspoonful) twice daily with food. Patients known to be easily sedated should begin treatment with 0.5 to 1 mg (1/2 to 1 teaspoonful) at night for the first few days.
Adults: 1 mg or 5 ml (1 teaspoonful) twice daily with food. If necessary the dose may be increased to 2 mg or 10 ml (2 teaspoonfuls) twice daily in severe cases.
Use in Elderly: Same as adult dose or as advised by the physician.
A reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agent and it has been suggested that this combination should therefore be avoided.
It is important to continue the previous treatment for a minimum of two weeks after starting Ketotifen to avoid the possibility of exacerbation of asthma. This applies specially to systemic corticosteroids and ACTH because of the possible existence of adrenocortical insufficiency in steroid dependent patients. If inter current infection occurs, Ketotifen treatment must be supplemented by specific antimicrobial therapy. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known. Patients should be advised to avoid alcoholic drinks. Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcoholics.
Drowsiness and in isolated cases dry mouth and slight dizziness may occur at the beginning of treatment but usually disappear spontaneously after a few days.
Use in Pregnancy and Lactation
Although there is no evidence of any teratogenic effect, Ketotifen in pregnancy and lactation is not recommended.
Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohols. A reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agents and it has been suggested that this combination should therefore be avoided.
The reported features of overdosage include confusion, drowsiness, headache, bradycardia, respiratory depression etc. Elimination of the drug with gastric lavage or emesis is recommended. Otherwise general supportive treatment is all that is required shall be instituted.
Store below 30⁰C, protect from light & moisture. Keep out of the reach of children.
Each box contains 100 ml syrup in a PET bottle with a measuring cup.